Quadrant Capital Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Quadrant Capital Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,131	Closed	-$20K	–	2792
2021 Q3	$20K	Buy	+1,131	New	+$13.2K	﹤0.01%	1255

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Quadrant Capital Group's TRIL Position: Q4 2021 in Review

Quadrant Capital Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,131 shares — an estimated $20K sold.

Quadrant Capital Group first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $20K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Quadrant Capital Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Quadrant Capital Group sold 1,131 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $20K.
Quadrant Capital Group first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Quadrant Capital Group's Trillium Therapeutics Inc. position peaked at $20K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Quadrant Capital Group's 13F filing for Q4 2021, filed 1 Feb 2022.